Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wai Yuen Tong Medicine HoldingsHKSE:00897 38 PB Ratio is 0.27 as of Aug. 23, 2026, which is 575% above its 10-year median of 0.04. GuruFocus rates HKSE:00897 with a GF Score™ of 38/100 and a GF Value™ of HK$0.29 (Fairly Valued). The stock has 2 warning signs investors should review. Among 920 Drug Manufacturers companies, Wai Yuen Tong Medicine Holdings ranks better than 97.17% on this metric.
Wai Yuen Tong Medicine Holdings Ltd stock PB Ratio (=0.27) is close to 1-year low of 0.26.
The historical rank and industry rank for Wai Yuen Tong Medicine Holdings's PB Ratio or its related term are showing as below:
HKSE:00897'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 0.45
Current: 0.27
During the past 13 years, Wai Yuen Tong Medicine Holdings's highest PB Ratio was 0.45. The lowest was 0.01. And the median was 0.04.
HKSE:00897's PB Ratio is ranked better than 97.17% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.975
vs HKSE:00897: 0.27
During the past 12 months, Wai Yuen Tong Medicine Holdings's average Book Value Per Share Growth Rate was 1.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -18.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -15.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -11.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Wai Yuen Tong Medicine Holdings was 46.10% per year. The lowest was -65.60% per year. And the median was -17.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Wai Yuen Tong Medicine Holdings PB Ratio Related Terms
Wai Yuen Tong Medicine Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wai Yuen Tong Medicine Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wai Yuen Tong Medicine Holdings PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wai Yuen Tong Medicine Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Wai Yuen Tong Medicine Holdings's PB Ratio falls into.
Wai Yuen Tong Medicine Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Wai Yuen Tong Medicine Holdings (HKSE:00897) has a PB Ratio of 0.27 as of Aug. 23, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. This is 575% above median its historical median of 0.04. Over the past decade, Wai Yuen Tong Medicine Holdings' PB Ratio has ranged from 0.01 to 0.45. According to the industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #26 out of 920 companies in the Drug Manufacturers industry, placing it in the top 2.8%.
Is Wai Yuen Tong Medicine Holdings' PB Ratio too high?
Wai Yuen Tong Medicine Holdings' current PB Ratio of 0.27 is 575% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.45. The Drug Manufacturers industry median PB Ratio is 1.98. Wai Yuen Tong Medicine Holdings' value of 0.27 is 86.3% below this industry median. Based on the distribution chart, Wai Yuen Tong Medicine Holdings ranks #26 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wai Yuen Tong Medicine Holdings has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wai Yuen Tong Medicine Holdings' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #26 out of 920 companies for PB Ratio. This places Wai Yuen Tong Medicine Holdings in the top 3% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.98. Wai Yuen Tong Medicine Holdings' value of 0.27 is 86.3% below this benchmark. Historically, Wai Yuen Tong Medicine Holdings' own PB Ratio has ranged from 0.01 to 0.45 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 1.98, Wai Yuen Tong Medicine Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wai Yuen Tong Medicine Holdings's current PB Ratio of 0.27 is 86.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wai Yuen Tong Medicine Holdings's current PB Ratio is 0.27, which is 575% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wai Yuen Tong Medicine Holdings stock overvalued right now?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings (HKSE:00897) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.29 — trading right at its estimated fair value. The current PB Ratio is 0.27, which is 575% above median its 10-year median of 0.04 and 86.3% below the Drug Manufacturers industry median of 1.98. Wai Yuen Tong Medicine Holdings' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Wai Yuen Tong Medicine Holdings (HKSE:00897), the current PB Ratio is 0.27 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wai Yuen Tong Medicine Holdings (HKSE:00897) Overvalued in 2026?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings stock appears to be undervalued.
The current stock price of HK$0.29 is trading 0% below its estimated GF Value™ of HK$0.29.
GuruFocus considers Wai Yuen Tong Medicine Holdings to be Fairly Valued.
Key valuation signals for HKSE:00897:
PB Ratio: 0.27 (575% above median its 10-year median of 0.04)
GF Value™: HK$0.29 vs. price of HK$0.29 (0% below fair value)
Industry Position: 86.3% below the Drug Manufacturers median (#26 of 920)
No single metric tells the full story. See the HKSE:00897 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.
38GF Score
Get the complete analysis for HKSE:00897
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00897 has been successfully added to your 
